详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Assay for Hepatitis B Core-related Antigen Identify Patients With High Viral Load: Systematic Review and Meta-analysis of Individual Participant Data.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Surgery and Cancer, Liver Unit, Imperial College London, Praed St, Paddington, London W2 1NY, UK. [2]Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, 25-28 Rue du Dr Roux, 75015 Paris, France. [3]Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea. [4]Laboratoire de Virologie, Centre de Biologie Pathologie, CHU de Lille, Boulevard du Professeur Jules Leclercq, 59037 Lille, France. [5]Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamakari, Inzai, Chiba 270-1694, Japan. [6]Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, University Hospital of Pisa, Lungarno Antonio Pacinotti, 43, 56126 Pisa PI, Italy. [7]Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron and Universitat Autònoma de Barcelona, Passeig Vall Hebron, 119-129, 08035, Barcelona, Spain. [8]Institute of Liver Studies, King's College Hospital, Denmark Hill, Brixton, London SE5 9RS, UK. [9]Department of Medical Sciences, University of Turin, Corso Dogliotti 14, Turin 10126, Italy. [10]Center of Infectious Diseases, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Wuhou District, Chengdu 610041, China. [11]Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany. [12]Department of Hepatology, Graduate School of Medicine, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan. [13]Department of Gastroenterology, and Department of Advanced Medical Technology, Kanazawa University Graduate School of Health Medicine, 13-1 Takara-Machi, Kanazawa, Ishikawa 920-8641, Japan. [14]Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan. [15]Toronto Centre for Liver Disease, Toronto General Hospital, University Of Toronto, 200 Elizabeth Street, Eaton Building 9th floor Room 234 (9EB234), Toronto, ON, Canada. [16]Center for Gastroenterology, Teine-Keijinkai Hospital, 12-1-40 Maeda-ichijo, Teine, Sapporo, Hokkaido 006-0811, Japan. [17]Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan. [18]Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawacho, Nishinomiya, Hyogo 663-8501, Japan. [19]Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. [20]Center of Excellence in Hepatitis and Liver cancer, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd, 10330, Bangkok, Thailand. [21]Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, 4-86 Minaminokawa, Ogaki, Gifu 503-8502, Japan. [22]Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. [23]Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, No. 11 Xizhimen South Street, Beijing 100044, China. [24]Genomics Research Center, Academia Sinica, 128 Academia Road, Nankang, Taipei 11529, Taiwan. [25]Center for Infectious Diseases, Department of Gastroenterology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. [26]Clinical Research Center, National Hospital Organization (NHO), Nagasaki Medical Center, 2-1001-1, Kubara, Omura, Nagasaki 856-8562, Japan. [27]Department of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China. [28]Department for the Promotion of Regional Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan. [29]Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho, Nagoya 467-8601, Japan.

出处：

DOI：

ISSN：

关键词： Hepatitis B Core-Related Antigen Diagnosis Sensitivity Specificity Systematic Review Meta-Analysis

摘要：

Scale-up of tests and treatments is needed to eliminate hepatitis B virus (HBV) infection from resource-limited countries. However, access to nucleic acid tests that quantify HBV DNA, to determine treatment eligibility, is severely limited. We performed a systematic review and meta-analysis to assess the performance of the hepatitis B core-related antigen (HBcrAg) immunoassay, a low-cost (less than $15/assay) alternative to the nucleic acid test, to identify highly viremic patients, infected with any HBV genotype. We searched Medline, Embase, Scopus, and Web of Science through June 27, 2018 for studies that measured HBV DNA and HBcrAg in the same blood samples. We contacted study authors to obtain data from each study participant, and randomly assigned each participant to the derivation or validation cohorts. We applied optimal HBcrAg cut-off values derived from the derivation set to the validation set to estimate sensitivity and specificity of HBcrAg to indicate high viremia. Of 74 eligible studies found in the systematic review, we obtained individual participant data from 60 studies (81%). We performed a meta-analysis of individual participant data of 5591 HBV-infected patients who did not receive antiviral therapy and 4806 HBV-infected patients who received antiviral agents. In untreated patients, the pooled area under the receiver operating characteristic curve and the optimal cut-off value for the HBcrAg assay were 0.88 (95% CI, 0.83-0.94) and 3.6 log U/ml for identifying patients with a level of HBV DNA ≥2000 IU/ml, and 0.96 (95% CI, 0.94-0.98) and 5.3 log U/ml for identifying patients with a level of HBV DNA ≥200,000 IU/ml, respectively. In the validation set, the HBcrAg assay identified patients with ≥2000 IU/ml HBV DNA with 85.2% sensitivity and 84.7% specificity; the assay identified patients with ≥200,000 IU/ml HBV DNA with 91.8% sensitivity and 90.5% specificity. Performance did not vary among HBV genotypes. In patients receiving anti-HBV therapy, there was no correlation between levels of HBcrAg and HBV DNA. In a systematic review and meta-analysis of individual participant data, we found that the assay for HBcrAg identifies treatment-naïve patients with high levels of HBV DNA with high sensitivity and specificity, regardless of genotype. The HBcrAg assay is a good, low-cost alternative to the nucleic acid test to identify highly viremic patients infected with different genotypes. Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区胃肠肝病学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区胃肠肝病学

第一作者：

第一作者机构： [1]Department of Surgery and Cancer, Liver Unit, Imperial College London, Praed St, Paddington, London W2 1NY, UK.

共同第一作者：

通讯作者：

通讯机构： [2]Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, 25-28 Rue du Dr Roux, 75015 Paris, France. [*1]Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, 25-28 Rue du Dr Roux, 75015 Paris, France.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Assay for Hepatitis B Core-related Antigen Identify Patients With High Viral Load: Systematic Review and Meta-analysis of Individual Participant Data.

文献详情

相关文献